- Home
- SNT vs ATYR Comparison
SNT vs ATYR Comparison
Compare SNT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | ATYR |
|---|---|---|
| Founded | 1965 | 2005 |
| Country | Canada | United States |
| Employees | N/A | 59 |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 83.3M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNT | ATYR |
|---|---|---|
| Price | $2.98 | $0.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $4.20 |
| AVG Volume (30 Days) | 25.2K | ★ 1.2M |
| Earning Date | 04-22-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $0.64 |
| 52 Week High | $5.34 | $7.29 |
Technical Indicators
Market Signals| Indicator | SNT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 41.25 |
| Support Level | $3.00 | $0.67 |
| Resistance Level | $4.45 | $0.85 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 18.60 | 5.33 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).